Auris Medical AG
Falknerstrasse 4
Basel
4001
Tel: 41-61-201-13-50
Fax: 41-61-201-13-51
Website: http://www.aurismedical.com/
181 articles about Auris Medical AG
-
Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2
7/14/2021
Auris Medical Holding Ltd. today nnounced additional preclinical data in a model of primary human nasal airway epithelium from its Bentrio™ (AM-301) nasal spray development program in SARS-CoV-2. AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation.
-
Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology
7/6/2021
Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the selection of mutant KRAS-driven colorectal cancer as the first therapeutic indication for its OligoPhore™ oligonucleotide delivery platform.
-
Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
6/28/2021
Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio™, its nasal spray for protection against airborne viruses and allergens, by launching it in Germany.
-
Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma
6/21/2021
Auris Medical Holding Ltd.today announced the publication of positive results from an in vivo study demonstrating significant inhibition of tumor growth by siRNA knock-down of NF-κB employing its OligoPhoreTM technology in Adult T-cell Leukemia Lymphoma (ATLL).
-
Auris Medical Announces Acquisition of RNA Therapeutics Company and Plans for Strategic Repositioning
6/3/2021
Entering field of RNA therapeutics through acquisition of Trasir Therapeutics, Inc. Trasir’s innovative peptide-based OligoPhore TM platform designed to enable extrahepatic delivery of oligonucleotides
-
Auris Medical Starts Preparations for Covid-19 Trial with Bentrio in India
6/1/2021
Auris Medical Holding Ltd., a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergology, announced that its affiliate Altamira Medica Ltd. has started preparations for the conduct of a study with its BentrioTM nasal spray for protection against airborne viruses and allergens in India.
-
Auris Medical Holding to Present at LD Micro Invitational XI Conference
5/28/2021
Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference
-
Auris Medical Announces Completion of Bentrio Conformity Assessment Procedure for Marketing in EU
5/25/2021
Meeting essential requirements for marketing Bentrio TM in Europe under CE mark On track for first product launch in Europe towards end of Q2 2021
-
Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo
5/14/2021
Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it has reached the midpoint for enrollment in Part B of its Phase 2 proof-of-concept trial of AM-125 (intranasal betahistine) in the treatment of acute peripheral vertigo.
-
Auris Medical Provides Update on Bentrio Program in Allergy
5/7/2021
Auris Medical Holding Ltd. (NASDAQ: EARS), and its affiliate Altamira Medica Ltd. today announced additional details on the outcomes from the clinical investigation of its BentrioTM nasal spray in allergic rhinitis and provided an update on the regulatory pathway in the US for the intended use in allergy.
-
With billions invested in R&D over the past year to find vaccines and therapies for the novel coronavirus, a few select life sciences companies and academic institutions are working on the hypothesis that intranasal vaccines and therapies could be key to stopping COVID-19 in its tracks, and provi...
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 8, 2020.
-
Auris Medical rose by as much as 480% yesterday after it announced lab test results, which appeared to show that its nasal spray could potentially protect users against COVID-19.
-
Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine
3/5/2020
Last subject had last treatment visit in Phase 1b trial with AM-201 in prevention of antipsychotic-induced weight gain and somnolence; data read-out expected for early May 2020
-
Auris Medical Announces Notice of Allowance for European Patent Application
1/10/2020
Auris Medical Holding Ltd. announced that the European Patent Office has issued a notice of “Intention to Grant” for its patent application entitled “Treatment of Tinnitus Through Modulation of Chloride Co-Transporter NKCC1 in the Auditory System”.
-
Auris Medical Announces Formation of New Subsidiary for Development Projects in Tinnitus and Hearing Loss
12/30/2019
Auris Medical Holding Ltd. announced the formation of a new subsidiary, Zilentin Ltd., to bundle its development projects for the treatment of tinnitus and hearing loss in a separate entity.
-
Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain
10/11/2019
Auris Medical Holding Ltd. announced positive interim results from its Phase 1b trial with AM-201 in antipsychotic-induced weight gain and somnolence.
-
Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program
9/13/2019
Auris Medical Holding Ltd. announced that it has obtained advice on the development plan and regulatory pathway for its investigational tinnitus treatment Keyzilen® from the U.S. Food and Drug Administration and from the European Medicines Agency.
-
Auris Medical Announces Notices of Allowance for U.S. and European Patent Applications Covering Intranasal Betahistine
9/11/2019
Received Notice of Allowance from United States Patent and Trademark Office -- Received “Intention to Grant” notice from European Patent Office
-
Auris Medical Announces Appointment of New Chief Financial Officer
9/4/2019
Auris Medical Holding Ltd. announced the appointment of Elmar Schärli, CPA, as new Chief Financial Officer, effective November 1, 2019.